By Owen Tucker-Smith
Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025.
Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in morning trading. The stock is about 35% below its 52-week peak of $275.
The company said there is a slowdown in its Discovery and Safety Assessment business, as spending from biopharma clients tightens globally due to restructuring programs and reprioritization efforts.
Charles River also said one of its clients is terminating its commercial agreement with the company, further weighing on revenue.
While the company said it will try to save money through restructuring initiatives, those efforts will not be enough to completely offset the anticipated revenue drop. Charles River expects its adjusted operating margin to fall below its expected 2024 level.
The company is scheduled to present its strategic focus, business developments and trends at the JPMorgan Healthcare Conference later Tuesday. It plans to report earnings in mid-February.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 14, 2025 11:23 ET (16:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。